A phase IIa trial of tipapkinogene sovacivec [TG 4001] in patients with human papillomavirus type 16-related cervical intraepithelial neoplasia.
Phase of Trial: Phase II
Latest Information Update: 11 Mar 2008
At a glance
- Drugs Tipapkinogene sovacivec (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 16 Nov 2006 New trial record.